Examining COVID-19 risks in MS

A large community-based study – believed to be the largest performed worldwide – has provided new data on COVID-19 risks in people with MS.

At MSVirtual2020, Dr Afagh Garjani from the Division of Clinical Neuroscience at the University of Nottingham, UK, presented preliminary findings of a COVID-19 study utilizing the United Kingdom MS Register (UKMSR).

Participants in the UKMSR were asked to join the COVID-19 study on 17 March 2020, just before lockdown was imposed in the UK. Social media was also used to advertise the study. Surveys were completed at initiation into the study and every 2 weeks afterwards.